{
    "symbol": "LCI",
    "quarter": 2,
    "year": 2023,
    "date": "2023-02-01 21:06:06",
    "content": " Further, for new product launches, excluding Fludarabine, we have forecasted sales of around $6 million in the back half of this fiscal year. Gross profit increased to $15.7 million, or 19% of net sales from $9.7 million or 11% of net sales for the prior year second quarter. At December 31st, total debt was approximately $659.4 million, comprised of first lien senior secured notes of $350 million, second lien notes of $223.1 million and convertible notes of $86.3 million. We expect the plan will begin generating savings in the current fiscal year, rising to approximately $11 million annually once fully implemented."
}